ObjectiveOpen surgical repair (OSR) for chronic type B aortic dissection (CTBAD) has an associated morbidity and mortality. The role of thoracic endovascular aortic repair (TEVAR) in CTBAD has not been determined. We analyzed our contemporary experience of CTBAD undergoing OSR to identify high-risk patients who may be considered for TEVAR.MethodsFrom 1999 to 2010, 221 patients had repair of descending thoracic and thoracoabdominal aortic aneurysms, including 86 patients with CTBADs. We analyzed this cohort for mortality, complications, length of stay, and reinterventions.ResultsOSR was performed in 25 (29%) and 61 (71%) patients for descending thoracic and thoracoabdominal CTBAD, respectively. Median age was 57.0 years (interquartile range ...
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) is applicable to a spectrum of thoracic aorti...
ObjectiveThe role of thoracic endovascular aortic repair (TEVAR) in the management of acute type B a...
IntroductionDespite a current lack of U.S. Food and Drug Administration approval for the indication,...
ObjectiveThe application of thoracic endovascular aortic repair (TEVAR) has changed treatment paradi...
Objective/backgroundRecently, the indications for thoracic endovascular aortic repair (TEVAR) have b...
Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) is unknown. ...
Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) is unknown. ...
BackgroundThe use of stent grafts and mortality of stent graft repair of type B thoracic aortic diss...
Background Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) i...
Background Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) i...
BACKGROUND:Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) i...
BackgroundThe Food and Drug Administration has approved devices for endovascular management of thora...
<div><p>Background</p><p>Currently, the optimal management strategy for chronic type B aortic dissec...
ObjectiveThoracic endovascular aortic repair (TEVAR) is applicable to a spectrum of thoracic aortic ...
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) is applicable to a spectrum of thoracic aorti...
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) is applicable to a spectrum of thoracic aorti...
ObjectiveThe role of thoracic endovascular aortic repair (TEVAR) in the management of acute type B a...
IntroductionDespite a current lack of U.S. Food and Drug Administration approval for the indication,...
ObjectiveThe application of thoracic endovascular aortic repair (TEVAR) has changed treatment paradi...
Objective/backgroundRecently, the indications for thoracic endovascular aortic repair (TEVAR) have b...
Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) is unknown. ...
Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) is unknown. ...
BackgroundThe use of stent grafts and mortality of stent graft repair of type B thoracic aortic diss...
Background Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) i...
Background Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) i...
BACKGROUND:Currently, the optimal management strategy for chronic type B aortic dissections (CBAD) i...
BackgroundThe Food and Drug Administration has approved devices for endovascular management of thora...
<div><p>Background</p><p>Currently, the optimal management strategy for chronic type B aortic dissec...
ObjectiveThoracic endovascular aortic repair (TEVAR) is applicable to a spectrum of thoracic aortic ...
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) is applicable to a spectrum of thoracic aorti...
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) is applicable to a spectrum of thoracic aorti...
ObjectiveThe role of thoracic endovascular aortic repair (TEVAR) in the management of acute type B a...
IntroductionDespite a current lack of U.S. Food and Drug Administration approval for the indication,...